Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells.

V. Speirs, M. J. Kerin, C. J. Newton, D. S. Walton, A. R. Green, S. B. Desai, Stephen Atkin

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Estrogen is mitogenic in breast cancer where IL-1beta also fulfils a role. The aim of this study was to determine any relationship between IL-1beta and ERalpha in breast cancer. By RT-PCR, 26/77 tumours expressed IL-1beta, and 57/77 expressed ERalpha. Samples which were IL-1beta positive were categorised against those which expressed ERalpha. Of the 26 tumours which expressed IL-1beta, all were ERalpha positive. We next examined whether IL-1beta could directly activate ERalpha. MCF-7 cells stably transfected with a plasmid reporter (ERE-TK-LUC) were incubated with either 17beta-estradiol (E2, 10-9-10-13 M), IL-1beta (10 ng/ml), the pure antiestrogen ZM 182780 (10 nM) or combinations of these substances. Transcriptional activity was measured in cell lysates 48 h later. E2 caused a dose-dependent increase in luciferase activity. With IL-1beta, transcriptional activity was typically half of the E2 response. To determine the role of the IL-1 receptor, parallel cultures were incubated with IL-1 receptor antagonist. This reduced, but did not completely block the effect of IL-1beta, suggesting that IL-1beta was affecting transcriptional activity via another pathway. Confirmation that the effect was via ERalpha was verified using the pure antiestrogen, ZM 182370, which completely abrogated the effects of E2, when added alone or in combination with IL-1beta. These results provide compelling evidence for direct transcriptional activation of ERalpha by IL-1beta. Interactions of these factors may thus modulate hormonal activity in human breast tumours.

Original languageEnglish
Pages (from-to)1251-1254
Number of pages4
JournalInternational Journal of Oncology
Volume15
Issue number6
Publication statusPublished - Dec 1999
Externally publishedYes

Fingerprint

Estrogen Receptor alpha
Transcriptional Activation
Breast Neoplasms
Estrogen Receptor Modulators
Interleukin-1 Receptors
MCF-7 Cells
Luciferases
Human Activities
Interleukin-10
Estradiol
Neoplasms
Estrogens
Plasmids
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Speirs, V., Kerin, M. J., Newton, C. J., Walton, D. S., Green, A. R., Desai, S. B., & Atkin, S. (1999). Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells. International Journal of Oncology, 15(6), 1251-1254.

Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells. / Speirs, V.; Kerin, M. J.; Newton, C. J.; Walton, D. S.; Green, A. R.; Desai, S. B.; Atkin, Stephen.

In: International Journal of Oncology, Vol. 15, No. 6, 12.1999, p. 1251-1254.

Research output: Contribution to journalArticle

Speirs, V, Kerin, MJ, Newton, CJ, Walton, DS, Green, AR, Desai, SB & Atkin, S 1999, 'Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells.', International Journal of Oncology, vol. 15, no. 6, pp. 1251-1254.
Speirs V, Kerin MJ, Newton CJ, Walton DS, Green AR, Desai SB et al. Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells. International Journal of Oncology. 1999 Dec;15(6):1251-1254.
Speirs, V. ; Kerin, M. J. ; Newton, C. J. ; Walton, D. S. ; Green, A. R. ; Desai, S. B. ; Atkin, Stephen. / Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells. In: International Journal of Oncology. 1999 ; Vol. 15, No. 6. pp. 1251-1254.
@article{82b9458d4ace48bd8daa1704a052eaf5,
title = "Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells.",
abstract = "Estrogen is mitogenic in breast cancer where IL-1beta also fulfils a role. The aim of this study was to determine any relationship between IL-1beta and ERalpha in breast cancer. By RT-PCR, 26/77 tumours expressed IL-1beta, and 57/77 expressed ERalpha. Samples which were IL-1beta positive were categorised against those which expressed ERalpha. Of the 26 tumours which expressed IL-1beta, all were ERalpha positive. We next examined whether IL-1beta could directly activate ERalpha. MCF-7 cells stably transfected with a plasmid reporter (ERE-TK-LUC) were incubated with either 17beta-estradiol (E2, 10-9-10-13 M), IL-1beta (10 ng/ml), the pure antiestrogen ZM 182780 (10 nM) or combinations of these substances. Transcriptional activity was measured in cell lysates 48 h later. E2 caused a dose-dependent increase in luciferase activity. With IL-1beta, transcriptional activity was typically half of the E2 response. To determine the role of the IL-1 receptor, parallel cultures were incubated with IL-1 receptor antagonist. This reduced, but did not completely block the effect of IL-1beta, suggesting that IL-1beta was affecting transcriptional activity via another pathway. Confirmation that the effect was via ERalpha was verified using the pure antiestrogen, ZM 182370, which completely abrogated the effects of E2, when added alone or in combination with IL-1beta. These results provide compelling evidence for direct transcriptional activation of ERalpha by IL-1beta. Interactions of these factors may thus modulate hormonal activity in human breast tumours.",
author = "V. Speirs and Kerin, {M. J.} and Newton, {C. J.} and Walton, {D. S.} and Green, {A. R.} and Desai, {S. B.} and Stephen Atkin",
year = "1999",
month = "12",
language = "English",
volume = "15",
pages = "1251--1254",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells.

AU - Speirs, V.

AU - Kerin, M. J.

AU - Newton, C. J.

AU - Walton, D. S.

AU - Green, A. R.

AU - Desai, S. B.

AU - Atkin, Stephen

PY - 1999/12

Y1 - 1999/12

N2 - Estrogen is mitogenic in breast cancer where IL-1beta also fulfils a role. The aim of this study was to determine any relationship between IL-1beta and ERalpha in breast cancer. By RT-PCR, 26/77 tumours expressed IL-1beta, and 57/77 expressed ERalpha. Samples which were IL-1beta positive were categorised against those which expressed ERalpha. Of the 26 tumours which expressed IL-1beta, all were ERalpha positive. We next examined whether IL-1beta could directly activate ERalpha. MCF-7 cells stably transfected with a plasmid reporter (ERE-TK-LUC) were incubated with either 17beta-estradiol (E2, 10-9-10-13 M), IL-1beta (10 ng/ml), the pure antiestrogen ZM 182780 (10 nM) or combinations of these substances. Transcriptional activity was measured in cell lysates 48 h later. E2 caused a dose-dependent increase in luciferase activity. With IL-1beta, transcriptional activity was typically half of the E2 response. To determine the role of the IL-1 receptor, parallel cultures were incubated with IL-1 receptor antagonist. This reduced, but did not completely block the effect of IL-1beta, suggesting that IL-1beta was affecting transcriptional activity via another pathway. Confirmation that the effect was via ERalpha was verified using the pure antiestrogen, ZM 182370, which completely abrogated the effects of E2, when added alone or in combination with IL-1beta. These results provide compelling evidence for direct transcriptional activation of ERalpha by IL-1beta. Interactions of these factors may thus modulate hormonal activity in human breast tumours.

AB - Estrogen is mitogenic in breast cancer where IL-1beta also fulfils a role. The aim of this study was to determine any relationship between IL-1beta and ERalpha in breast cancer. By RT-PCR, 26/77 tumours expressed IL-1beta, and 57/77 expressed ERalpha. Samples which were IL-1beta positive were categorised against those which expressed ERalpha. Of the 26 tumours which expressed IL-1beta, all were ERalpha positive. We next examined whether IL-1beta could directly activate ERalpha. MCF-7 cells stably transfected with a plasmid reporter (ERE-TK-LUC) were incubated with either 17beta-estradiol (E2, 10-9-10-13 M), IL-1beta (10 ng/ml), the pure antiestrogen ZM 182780 (10 nM) or combinations of these substances. Transcriptional activity was measured in cell lysates 48 h later. E2 caused a dose-dependent increase in luciferase activity. With IL-1beta, transcriptional activity was typically half of the E2 response. To determine the role of the IL-1 receptor, parallel cultures were incubated with IL-1 receptor antagonist. This reduced, but did not completely block the effect of IL-1beta, suggesting that IL-1beta was affecting transcriptional activity via another pathway. Confirmation that the effect was via ERalpha was verified using the pure antiestrogen, ZM 182370, which completely abrogated the effects of E2, when added alone or in combination with IL-1beta. These results provide compelling evidence for direct transcriptional activation of ERalpha by IL-1beta. Interactions of these factors may thus modulate hormonal activity in human breast tumours.

UR - http://www.scopus.com/inward/record.url?scp=0033450480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033450480&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 1251

EP - 1254

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -